Equities

North China Pharmaceutical Co Ltd

600812:SHH

North China Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)4.55
  • Today's Change-0.06 / -1.30%
  • Shares traded6.30m
  • 1 Year change-19.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5051,0555,049
Total Receivables, Net4,0194,3354,591
Total Inventory2,6082,5232,392
Prepaid expenses282269211
Other current assets, total603801470
Total current assets8,0188,98312,712
Property, plant & equipment, net7,4737,8698,251
Goodwill, net3.343.343.34
Intangibles, net4,0793,2792,956
Long term investments1,220918876
Note receivable - long term------
Other long term assets------
Total assets20,95721,22124,930
LIABILITIES
Accounts payable1,9091,9532,125
Accrued expenses202234306
Notes payable/short-term debt6,0786,1588,478
Current portion long-term debt/capital leases1,3003,2302,523
Other current liabilities, total779834808
Total current liabilities10,26912,40914,240
Total long term debt4,3802,5423,627
Total debt11,75811,93114,628
Deferred income tax------
Minority interest955928932
Other liabilities, total384145
Total liabilities15,64115,92118,844
SHAREHOLDERS EQUITY
Common stock1,7161,7161,716
Additional paid-in capital3,8993,8863,886
Retained earnings (accumulated deficit)(306)(310)481
Treasury stock - common------
Unrealized gain (loss)--2.833.18
Other equity, total6.335.51(0.75)
Total equity5,3155,3006,085
Total liabilities & shareholders' equity20,95721,22124,930
Total common shares outstanding1,7161,7161,716
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.